Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImmunoGen’s Mirvetuximab Confidence Justified With Ovarian Cancer Win

Success Follows Accelerated Approval Setback In 2019

Executive Summary

The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.

You may also be interested in...



ASCO Data Could Clarify Ocular Toxicity Concerns For ImmunoGen’s Mirvetuximab

ImmunoGen may need to mount an aggressive education campaign to get in front of issues like blurred vision and keratopathy, with ocular toxicity being common among antibody-drug conjugates.

Keeping Track: Novel Oncologics Submitted By Taiho, ImmunoGen, Y-mAbs; US FDA Declines Akebia’s Vadadustat

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel